This is a routine investor presentation filing with no new material information. Monitor for future 6-K filings or press releases regarding the ATH434 Phase 3 program for MSA, which is the key catalyst for the stock.
Price Chart
Executive Summary
Alterity Therapeutics filed a 6-K furnishing a corporate presentation for September 2026. The filing contains no new material financial data, operational updates, or catalysts beyond what was previously disclosed in the annual 20-F report. The presentation slides are attached as graphic images with no extractable text content in the filing documents.
Key Facts
- Filed a 6-K on September 23, 2026, furnishing a Corporate Presentation for September 2026 as Exhibit 99.1
- The presentation consists of 51 slide images with no extractable text in the filing documents
- No new financial figures, guidance, or material business developments were disclosed in the filing text
- The filing is incorporated by reference into existing S-8 and F-3 registration statements
Financial Impact
No financial figures disclosed in this filing
Risk Factors
- No new information provided — stock may trade on prior disclosures and broader biotech sentiment
- Going concern risk previously disclosed in the 20-F remains relevant
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001437749-26-030992 |
| Document: athe20260922_6k.htm | 0001437749-26-030992 |
| Document: 0001437749-26-030992-index-headers.html | 0001437749-26-030992 |
| Document: 0001437749-26-030992-index.html | 0001437749-26-030992 |
| Document: 0001437749-26-030992.txt | 0001437749-26-030992 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 23, 2026 4d ago | 6-K | $2.09 | awaiting T+60 | — | $2.08 (+0.48%) |
Oct 23, 2026 4d ago | 6-K | $2.09 | awaiting T+60 | — | $2.08 (−0.48%) |
Oct 23, 2026 4d ago | 6-K | $2.09 | awaiting T+60 | — | $2.08 (−0.48%) |
Oct 21, 2026 6d ago | 6-K | $2.39 | awaiting T+60 | — | $2.08 (−12.97%) |
Oct 21, 2026 6d ago | 6-K | $2.39 | awaiting T+60 | — | $2.08 (−12.97%) |
Oct 19, 2026 8d ago | 6-K | $2.43 | awaiting T+60 | — | $2.08 (−14.40%) |
Oct 9, 2026 18d ago | 6-K | $3.12 | awaiting T+60 | — | $2.08 (−33.33%) |
Oct 5, 2026 22d ago | Press Release | $3.22 | awaiting T+60 | — | $2.08 (−35.40%) |
Oct 5, 2026 22d ago | 6-K | $3.22 | awaiting T+60 | — | $2.08 (−35.40%) |
Sep 25, 2026 4w ago | 6-K | $3.67 | awaiting T+60 | — | $2.08 (−43.32%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers